The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens.
Marzia Capelletti
No relevant relationships to disclose
Doron Lipson
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Geoff Otto
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Roman Yelensky
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Dalia Ercan
No relevant relationships to disclose
Jhingook Kim
No relevant relationships to disclose
Hidefumi Sasaki
No relevant relationships to disclose
Hyeong Ryul Kim
No relevant relationships to disclose
Seung-Il Park
No relevant relationships to disclose
Jeffrey S. Ross
Consultant or Advisory Role - Foundation Medicine
Philip Stephens
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Maureen T. Cronin
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Pasi Antero Janne
Consultant or Advisory Role - Abbott Laboratories; AstraZeneca; Boehringer Ingelheim; FORMA Therapeutics; Genentech; Pfizer; Quintiles/TMD; Roche
Other Remuneration - LabCorp